{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:21:04Z","timestamp":1790418064872,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012197","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000}}],"reference-count":172,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012197.pub2","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T17:16:00Z","timestamp":1525454160000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pharmacological interventions for apathy in Alzheimer's disease"],"prefix":"10.1002","volume":"2018","author":[{"given":"Myuri T","family":"Ruthirakuhan","sequence":"first","affiliation":[{"name":"Sunnybrook Research Institute; Hurvitz Brain Sciences Research Program; 2075 Bayview Avenue Toronto ON Canada M4N 3M5"},{"name":"University of Toronto; Department of Pharmacology and Toxicology; 2075 Bayview Avenue Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute; Hurvitz Brain Sciences Research Program; 2075 Bayview Avenue Toronto ON Canada M4N 3M5"},{"name":"University of Toronto; Department of Psychiatry; 2075 Bayview Avenue, Room H-185 Toronto ON Canada"},{"name":"Sunnybrook Health Sciences Centre; Geriatric Psychiatry; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleenor H","family":"Abraham","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute; Hurvitz Brain Sciences Research Program; 2075 Bayview Avenue Toronto ON Canada M4N 3M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chan","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre; Neuropsychopharmacology Research Group; 2075 Bayview Avenue Toronto Canada M4N 3M5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L","family":"Lanct\u00f4t","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute; Hurvitz Brain Sciences Research Program; 2075 Bayview Avenue Toronto ON Canada M4N 3M5"},{"name":"University of Toronto; Department of Pharmacology and Toxicology; 2075 Bayview Avenue Toronto Canada"},{"name":"University of Toronto; Department of Psychiatry; 2075 Bayview Avenue, Room H-185 Toronto ON Canada"},{"name":"Sunnybrook Health Sciences Centre; Geriatric Psychiatry; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","article-title":"Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study","volume":"173","author":"Leonpacher","year":"2016","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012197.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"The Journal of the American Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.1032","article-title":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease","volume":"19","author":"Deyn","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012197.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4088\/JCP.10m06708","article-title":"A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease","volume":"73","author":"Frakey","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012197.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00019442-200506000-00012","article-title":"Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials","volume":"13","author":"Herrmann","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000097757","article-title":"A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease","volume":"23","author":"Herrmann","year":"2007","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/JCP.0b013e318172b479","article-title":"Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge","volume":"28","author":"Herrmann","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jamda.2015.08.019","article-title":"A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease","volume":"17","author":"Herrmann","year":"2016","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000051193","article-title":"Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease","volume":"9 Suppl 2","author":"Kaufer","year":"1998","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"6","key":"10.1002\/14651858.CD012197.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/gps.636","article-title":"Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease","volume":"17","author":"Lanct\u00f4t","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1212\/WNL.50.5.1222","article-title":"Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease","volume":"50","author":"Morris","year":"1998","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD012197.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/gps.1325","article-title":"Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial","volume":"20","author":"Feldman","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S104161020200858X","article-title":"Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease","volume":"14","author":"Gauthier","year":"2002","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0015|cit15","first-page":"appiajp20171703","article-title":"Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer's disease: a double-blind, randomized, placebo-controlled trial","volume":"175","author":"Padala","year":"2017","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4088\/JCP.v60n0510","article-title":"The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group","volume":"60","author":"Raskind","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD012197.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4088\/JCP.12m08099","article-title":"Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial","volume":"74","author":"Rosenberg","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD012197.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/gps.1998","article-title":"Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home study (BEDNURS)","volume":"23","author":"Ruths","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3233\/JAD-151113","article-title":"Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease","volume":"54","author":"Rosenberg","year":"2016","journal-title":"Journal of Alzheimer's Disease"},{"issue":"6","key":"10.1002\/14651858.CD012197.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gps.653","article-title":"Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial","volume":"17","author":"Sival","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012197.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"issue":"8","key":"10.1002\/14651858.CD012197.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1017\/S1041610212002141","article-title":"Mibampator (LY451395) randomized clinical trial for agitation\/aggression in Alzheimer's disease","volume":"25","author":"Trzepacz","year":"2013","journal-title":"International Psychogeriatrics"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4088\/JCP.v65n0120","article-title":"A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome","volume":"65","author":"Ballard","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7496","key":"10.1002\/14651858.CD012197.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"The British Medical Journal (Clinical research ed.)"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0050076","article-title":"A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)","volume":"5","author":"Ballard","year":"2008","journal-title":"PLoS Medicine"},{"issue":"9789","key":"10.1002\/14651858.CD012197.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(11)60830-1","article-title":"Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial","volume":"378","author":"Banerjee","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0197-4580(04)80639-0","article-title":"Dose-ranging study of aripiprazole in patients with dementia of Alzheimer's disease","volume":"25","author":"Breder","year":"2004","journal-title":"Neurobiology of Aging"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/089198879701000306","article-title":"Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study","volume":"10","author":"Bridges-Parlet","year":"1997","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia","volume":"64","author":"Brodaty","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease - results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"15","key":"10.1002\/14651858.CD012197.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.159.15.1733","article-title":"Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study","volume":"159","author":"Cohen-Mansfield","year":"1999","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012197.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/00019442-200508000-00012","article-title":"Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia","volume":"13","author":"Deberdt","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"Deyn","year":"1999","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","article-title":"Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study","volume":"25","author":"Deyn","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012197.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.2630","article-title":"A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease","volume":"26","author":"Devanand","year":"2011","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"16","key":"10.1002\/14651858.CD012197.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer's disease","volume":"367","author":"Devanand","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000102570","article-title":"A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia","volume":"24","author":"Vasconcelos Cunha","year":"2007","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.930040210","article-title":"Double-blind controlled withdrawal of thioridazine treatment in elderly female inpatients with senile dementia","volume":"4","author":"Findlay","year":"1989","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012197.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer's disease","volume":"366","author":"Howard","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group","volume":"60","author":"Katz","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012197.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.60.7.737","article-title":"Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS","volume":"60","author":"Lyketsos","year":"2003","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00019442-200002000-00009","article-title":"A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease","volume":"8","author":"Magai","year":"2000","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","article-title":"Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial","volume":"14","author":"Mintzer","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1600-0447.1992.tb03242.x","article-title":"A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia","volume":"86","author":"Nyth","year":"1992","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1176\/jnp.8.3.270","article-title":"A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease","volume":"8","author":"Petracca","year":"1996","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S104161020100761X","article-title":"A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease","volume":"13","author":"Petracca","year":"2001","journal-title":"International Psychogeriatrics"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1176\/ajp.146.1.45","article-title":"Double-blind trial of imipramine in Alzheimer's disease patients with and without depression","volume":"146","author":"Reifler","year":"1989","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","article-title":"Sertraline for the treatment of depression in Alzheimer disease","volume":"18","author":"Rosenberg","year":"2010","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"7184","key":"10.1002\/14651858.CD012197.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"The British Medical Journal (Clinical research ed.)"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1192\/bjp.168.2.149","article-title":"Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial","volume":"168","author":"Roth","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0057|cit57","first-page":"534","article-title":"A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients","volume":"31","author":"Satterlee","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"15","key":"10.1002\/14651858.CD012197.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial","volume":"61","author":"Seltzer","year":"2004","journal-title":"Archives of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012197.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group","volume":"57","author":"Street","year":"2000","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/S0197-4580(04)80643-2","article-title":"Flexible-dose aripiprazole in psychosis of Alzheimer's disease","volume":"25","author":"Steim","year":"2004","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0062|cit62","first-page":"11","article-title":"Efficacy of atypical antipsychotics in elderly patients with dementia","volume":"65 Suppl 11","author":"Tariot","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0063|cit63","unstructured":"Tariot P Medication helps quell the agitation of dementia www.urmc.rochester.edu\/pr\/news\/story.cfm?id=593 2004"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1041610202008396","article-title":"A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia","volume":"14","author":"Reekum","year":"2002","journal-title":"International Psychogeriatrics"},{"issue":"7274","key":"10.1002\/14651858.CD012197.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group","volume":"321","author":"Wilcock","year":"2000","journal-title":"The British Medical Journal (Clinical research ed.)"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00279186","article-title":"Transmission of a t(13q22q) chromosome observed in three generations with segregation of the translocation D1-trisomy syndrome","volume":"30","author":"Abe","year":"1975","journal-title":"Humangenetik"},{"issue":"1615","key":"10.1002\/14651858.CD012197.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"20120535","DOI":"10.1098\/rstb.2012.0535","article-title":"The neurobiology of depression--revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies","volume":"368","author":"Albert","year":"2013","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000117341","article-title":"Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease","volume":"30","author":"Allard","year":"1990","journal-title":"European Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012197.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"e1320","DOI":"10.4088\/JCP.15f10377","article-title":"The primary outcome measure and its importance in clinical trials","volume":"76","author":"Andrade","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0071|cit71","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0072|cit72","first-page":"206","article-title":"The overlap between vascular disease and Alzheimer's disease--lessons from pathology","volume":"12","author":"Attems","year":"2014","journal-title":"BioMed Central Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003476.pub2","article-title":"Atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00131746-200405000-00010","article-title":"SSRI-induced apathy syndrome: a clinical review","volume":"10","author":"Barnhart","year":"2004","journal-title":"Journal of Psychiatric Practice"},{"issue":"4558","key":"10.1002\/14651858.CD012197.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/JGP.0b013e31822001a6","article-title":"Pharmacologic treatment of apathy in dementia","volume":"20","author":"Berman","year":"2012","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0077|cit77","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00019442-200303000-00012","article-title":"Executive dysfunction and apathy predict functional impairment in Alzheimer disease","volume":"11","author":"Boyle","year":"2003","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.2005.00540.x","article-title":"The role of dopamine in reward and pleasure behaviour--review of data from preclinical research","volume":"427","author":"Bressan","year":"2005","journal-title":"Acta Psychiatrica Scandinavica. Supplement"},{"issue":"9","key":"10.1002\/14651858.CD012197.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1176\/appi.ajp.2012.11101529","article-title":"Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia","volume":"169","author":"Brodaty","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"5-6","key":"10.1002\/14651858.CD012197.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000445873","article-title":"Agomelatine Improves apathy in frontotemporal dementia","volume":"16","author":"Callegari","year":"2016","journal-title":"Neuro-Degenerative Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jpsychores.2010.01.012","article-title":"Are the available apathy measures reliable and valid? A review of the psychometric evidence","volume":"70","author":"Clarke","year":"2011","journal-title":"Journal of Psychosomatic Research"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/089198870101400211","article-title":"Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease","volume":"14","author":"Cummings","year":"2001","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0891988715573534","article-title":"Apathy in neurodegenerative diseases: recommendations on the design of clinical trials","volume":"28","author":"Cummings","year":"2015","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clineuro.2007.08.007","article-title":"Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction","volume":"110","author":"David","year":"2008","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"1-3","key":"10.1002\/14651858.CD012197.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2005.09.065","article-title":"5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis","volume":"526","author":"Boer","year":"2005","journal-title":"European Journal of Pharmacology"},{"issue":"16","key":"10.1002\/14651858.CD012197.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1523\/JNEUROSCI.18-16-06528.1998","article-title":"Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors","volume":"18","author":"Deurwaerd\u00e8re","year":"1998","journal-title":"Journal of Neuroscience"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00415-002-0903-1","article-title":"Levodopa and bromocriptine in hypoxic brain injury","volume":"249","author":"Debette","year":"2002","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007726.pub2","article-title":"Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia","author":"Declercq","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0092|cit92","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12439-013-0035-3","article-title":"Interpreting change scores of the Behavioural Rating Scale for Geriatric Inpatients (GIP)","volume":"44","author":"Diesfeldt","year":"2013","journal-title":"Tijdschrift voor Gerontologie en Geriatrie"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD012197.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"The British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ana.410200510","article-title":"A postmortem study of amino acid neurotransmitters in Alzheimer's disease","volume":"20","author":"Ellison","year":"1986","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD012197.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/gps.1325","article-title":"Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial","volume":"20","author":"Feldman","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1192\/bjp.163.3.364","article-title":"Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease","volume":"163","author":"F\u00f6rstl","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","article-title":"Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease","volume":"43","author":"Garcia-Alloza","year":"2005","journal-title":"Neuropsychologia"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S104161020200858X","article-title":"Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease","volume":"14","author":"Gauthier","year":"2002","journal-title":"International Psychogeriatrics"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0103|cit103","first-page":"14","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"81","author":"General Assembly of the World Medical Association","year":"2014","journal-title":"The Journal of the American College of Dentists"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0104|cit104","first-page":"349","article-title":"Mechanisms of modafinil: A review of current research","volume":"3","author":"Gerrard","year":"2007","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"19","key":"10.1002\/14651858.CD012197.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2012.36918","article-title":"Nonpharmacologic management of behavioral symptoms in dementia","volume":"308","author":"Gitlin","year":"2012","journal-title":"The Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/978-0-387-79948-3_1895","article-title":"Frontal systems behavior scale","author":"Grace","year":"2011","journal-title":"Encyclopedia of Clinical Neuropsychology"},{"issue":"7650","key":"10.1002\/14651858.CD012197.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"The British Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD012197.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11920-016-0737-7","article-title":"Apathy in dementia: systematic review of recent evidence on pharmacological treatments","volume":"18","author":"Harrison","year":"2016","journal-title":"Current Psychiatry Reports"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/jnp.16.3.261","article-title":"The role of norepinephrine in the behavioral and psychological symptoms of dementia","volume":"16","author":"Herrmann","year":"2004","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"9","key":"10.1002\/14651858.CD012197.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.psyneuen.2004.02.001","article-title":"Growth hormone response to clonidine predicts aggression in Alzheimer's disease","volume":"29","author":"Herrmann","year":"2004","journal-title":"Psychoneuroendocrinology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012197.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/alzrt201","article-title":"Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian consensus conference on the diagnosis and treatment of dementia 2012","volume":"5","author":"Herrmann","year":"2013","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0113|cit113","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004714-199010000-00007","article-title":"Apathy and indifference in patients on fluvoxamine and fluoxetine","volume":"10","author":"Hoehn-Saric","year":"1990","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000149584","article-title":"Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia","volume":"26","author":"Hurt","year":"2008","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"The British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/WAD.0b013e318231e5fc","article-title":"Regional cerebral blood flow abnormalities associated with apathy and depression in Alzheimer's disease","volume":"26","author":"Kang","year":"2012","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbadis.2015.12.023","article-title":"Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons","volume":"1862","author":"Kapasi","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/jnp.10.1.55","article-title":"Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity","volume":"10","author":"Kaufer","year":"1998","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000051193","article-title":"Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease","volume":"9 Suppl 2","author":"Kaufer","year":"1998","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mad.2005.09.016","article-title":"Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease","volume":"127","author":"Lanari","year":"2006","journal-title":"Mechanisms of Ageing and Development"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/jnp.13.1.5","article-title":"Role of serotonin in the behavioral and psychological symptoms of dementia","volume":"13","author":"Lanct\u00f4t","year":"2001","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1017\/S1041610206003899","article-title":"Behavioral correlates of GABAergic disruption in Alzheimer's disease","volume":"19","author":"Lanct\u00f4t","year":"2007","journal-title":"International Psychogeriatrics"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000103633","article-title":"A SPECT study of apathy in Alzheimer's disease","volume":"24","author":"Lanct\u00f4t","year":"2007","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1700-7","DOI":"10.1046\/j.1532-5415.2001.49282.x","article-title":"Apathy in Alzheimer\u2019s disease","volume":"49","author":"Landes","year":"2001","journal-title":"Journal of the American Geriatrics Society"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","article-title":"Effects of citalopram on neuropsychiatric symptoms in Alzheimer'sdDementia: evidence from the CitAD Study","volume":"173","author":"Leonpacher","year":"2016","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1176\/jnp.10.3.314","article-title":"Apathy is not depression","volume":"10","author":"Levy","year":"1998","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"7400","key":"10.1002\/14651858.CD012197.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"The British Medical Journal (Clinical research ed.)"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003945.pub3","article-title":"Valproate preparations for agitation in dementia","author":"Lonergan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Pt 4","key":"10.1002\/14651858.CD012197.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/brain\/111.4.785","article-title":"Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease","volume":"111","author":"Lowe","year":"1988","journal-title":"Brain"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-1781(91)90040-V","article-title":"Reliability and validity of the apathy evaluation scale","volume":"38","author":"Marin","year":"1991","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD012197.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00005053-199404000-00008","article-title":"Group differences in the relationship between apathy and depression","volume":"182","author":"Marin","year":"1994","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1176\/jnp.7.1.23","article-title":"Apathy: a treatable syndrome","volume":"7","author":"Marin","year":"1995","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"7","key":"10.1002\/14651858.CD012197.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's & Dementia"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1755-5949.2010.00161.x","article-title":"The role of\u00a0dopamine\u00a0in symptoms and treatment of apathy in Alzheimer's disease","volume":"17","author":"Mitchell\u00a0RA","year":"2011","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/gps.2508","article-title":"Diagnostic criteria for apathy in clinical practice","volume":"26","author":"Mulin","year":"2011","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012197.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.4088\/JCP.14r09237","article-title":"Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials","volume":"76","author":"O'Regan","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"19","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14737175.4.5.809","article-title":"Nonpharmacological and pharmacological interventions for symptoms in Alzheimer's disease","volume":"4","author":"Overshott","year":"2004","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1345\/aph.1H302","article-title":"Modafinil therapy for apathy in an elderly patient","volume":"41","author":"Padala","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/gps.1045","article-title":"Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviors among referrals to a memory clinic","volume":"19","author":"Politis","year":"2004","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012197.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"The Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0147|cit147","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eurpsy.2008.09.001","article-title":"Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders","volume":"24","author":"Robert","year":"2009","journal-title":"European Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0149|cit149","first-page":"1330","article-title":"Use of psychostimulants for the elderly","volume":"41","author":"Roccaforte","year":"1990","journal-title":"Hospital & Community Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial.","volume":"71","author":"Rockwood","year":"2001","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3233\/JAD-151113","article-title":"Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease","volume":"54","author":"Rosenberg","year":"2016","journal-title":"Journal of Alzheimer's Disease : JAD"},{"issue":"Pt 2","key":"10.1002\/14651858.CD012197.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/brain\/105.2.313","article-title":"A post-mortem study of the cholinergic and GABA systems in senile dementia","volume":"105","author":"Rossor","year":"1982","journal-title":"Brain"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study","volume":"11 Suppl 2","author":"Schneider","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"24","key":"10.1002\/14651858.CD012197.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","article-title":"Mixed brain pathologies account for most dementia cases in community-dwelling older persons","volume":"69","author":"Schneider","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jech.2010.119933","article-title":"The GRADE approach and Bradford Hill's criteria for causation","volume":"65","author":"Sch\u00fcnemann","year":"2011","journal-title":"Journal of Epidemiology and Community Health"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008191.pub2","article-title":"Antidepressants for agitation and psychosis in dementia","author":"Seitz","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/cjn.2016.426","article-title":"Pharmacological therapy for apathy in Alzheimer's disease: a systematic review and meta-analysis","volume":"44","author":"Sepehry","year":"2017","journal-title":"Canadian Journal of Neurological Sciences."},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/jnnp.63.1.66","article-title":"Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer's disease","volume":"63","author":"Starkstein","year":"1997","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/jnp.2009.21.3.259","article-title":"Neuroimaging correlates of apathy and depression in Alzheimer's disease","volume":"21","author":"Starkstein","year":"2009","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study","volume":"23","author":"Steinberg","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0304-3940(95)12256-7","article-title":"Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients","volume":"203","author":"Storga","year":"1996","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.archger.2008.09.002","article-title":"Depression and apathy in dementia: same syndrome or different constructs? A critical review","volume":"49","author":"Tagariello","year":"2009","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"12","key":"10.1002\/14651858.CD012197.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012197.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.72","article-title":"Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease","volume":"49","author":"Tekin","year":"2001","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.bp.114.148403","article-title":"Longitudinal course of behavioural and psychological symptoms of dementia: systematic review","volume":"209","author":"Linde","year":"2016","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1600-0447.1995.tb09793.x","article-title":"Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia","volume":"91","author":"Vartiainen","year":"1995","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD012197.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/JAD-2012-120913","article-title":"Apathy syndrome in Alzheimer's disease epidemiology: prevalence, incidence, persistence, and risk and mortality factors","volume":"33","author":"Vilalta-Franch","year":"2013","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/070674370200601S05","article-title":"Mechnism of action of methylphenidate: Insights from PET imaging studies","volume":"6","author":"Volkow","year":"2002","journal-title":"Journal of Attention Disorders"},{"issue":"1","key":"10.1002\/14651858.CD012197.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s002130050210","article-title":"Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine","volume":"130","author":"Walsh","year":"1997","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0170|cit170","unstructured":"World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: clinical descriptions and diagnostic guidelines. 1992 apps.who.int\/iris\/handle\/10665\/37958#sthash.Vaxjp53U.dpuf"},{"key":"10.1002\/14651858.CD012197.pub2-BIB0171|cit171","unstructured":"Prince M Wimo A Guerchet M Ali G Wu Y Prina M World Alzheimer Report 2015: The Global Impact of Dementia www.worldalzreport2015.org\/downloads\/world-alzheimer-report-2015.pdf"},{"issue":"5","key":"10.1002\/14651858.CD012197.pub2-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012197","article-title":"Pharmacological interventions for apathy in Alzheimer's disease (Protocol)","author":"Ruthirakuhan","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012197.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T08:05:34Z","timestamp":1630310734000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012197.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":172,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012197.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,4]]}}}